Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton, Dickinson and Company

https://www.bd.com/en-us

Latest From Becton, Dickinson and Company

PBM Execs Stay On Message Amid Growing US Congressional Frustration At Hearing

The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.

Reimbursement Legislation

Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room. 

Digital Health Roundup Digital Health

Dovato Shows Signs Of Weight-Gain Advantage Over Biktarvy

A Phase IV study showed that ViiV’s Dovato was non-inferior to Gilead’s Biktarvy on efficacy and produced less weight gain.

Post Market Regulation & Studies Infectious Diseases

Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives

Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.

Restructuring Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • BD
    • BD Medical
    • Bridger Biomed, Inc.
    • Caesarea Medical Electronics
    • CareFusion
    • Carmel Pharma, Inc.
    • Carmel Pharma, AB
    • Cellular Research, Inc.
    • C.R. Bard, Inc.
    • CRISI Medical Systems
    • Davol, Inc.
    • Embo Medical Limited
    • FlowCardia, Inc.
    • GenCell Biosystems, Ltd.
    • GeneOhm Sciences
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Sirigen Group Limited
    • TriPath Imaging
    • TVA Medical, Inc.
    • Rochester Medical, Inc.
    • Safety Syringes Inc.
    • Vascular Pathways, Inc.
    • Venclose, Inc.
UsernamePublicRestriction

Register